The National Institutes of Health (NIH) has issued research findings showing that hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with novel coronavirus (COVID-19).  NIH notes that research demonstrated that even adding hyperimmune intravenous immunoglobulin to a remdesivir regimen did not improve the health of adults hospitalized with COVID-19 and may be harmful for a certain subset of patients.  To read the NIH announcement and summary of the research findings on hyperimmune intravenous immunoglobulin not improving outcomes for adult patients hospitalized with COVID-19, use the link below.
https://www.nih.gov/news-events/news-releases/hyperimmune-intravenous-immunoglobulin-does-not-improve-outcomes-adults-hospitalized-covid-19